Turn Therapeutics (TTRX)
Develops GX-03 for skin disease while licensing medical-device products.
$9.82
At close−0.00 (−0.05%)
In millions of USD, except per-share figures
| In millions | Q2 FY24Jun 2024 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|
| Cost of revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross profit | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 1 | 2 | 2 | 1 | 2 | |
| Research & development | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 1 | 2 | 2 | 1 | 1 | |
| General & administrative | 0 | 1 | 0 | 0 | 0 | 0 |
| Operating income | 0 | −1 | −2 | −2 | −1 | −2 |
| 0 | 0 | 0 | 2 | 0 | −4 | |
| Interest income | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | 0 | 0 | −2 | 0 | 0 |
| Income before tax | 0 | −1 | −2 | 0 | −1 | −6 |
| Net income from continuing operations | 0 | −1 | −2 | 0 | −1 | −6 |
| Net income | 0 | −1 | −2 | 0 | −1 | −6 |
| EPS, basic | −$0.03 | −$0.09 | −$0.07 | $0.01 | −$0.03 | −$0.20 |
| EPS, diluted | −$0.03 | −$0.09 | −$0.07 | $0.01 | −$0.03 | −$0.20 |
| Weighted average shares, basic | 13 | 14 | 28 | 29 | 29 | 30 |
| Weighted average shares, diluted | 13 | 14 | 28 | 29 | 29 | 30 |
| EBITDA | 0 | −1 | −2 | 0 | −1 | −2 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | 0 | −1 | −2 | 0 | −1 | −2 |